Tarsus Pharmaceuticals, Inc.: files amendment including pro forma financial information

What happened Tarsus Pharmaceuticals, Inc. filed Amendment No. 1 to its Form 8-K on Oct 13, 2026. The amendment includes pro forma financial information related to the company and Alkeus and states the pro forma information "has been presented for informational purposes only, as required by Form 8-K." The filing says the pro forma information "does not purport to represent the actual results of operations that the Company and Alkeus would have achieved had the companies been combined during the periods presented" and "is not intended to project the future results of operations that the combined company may achieve following completion of the Acquisition."

Key details

• Item 9.01 reported: financial statements and exhibits — Amendment No. 1 adds pro forma financial information.
• The pro forma information concerns Tarsus and Alkeus and the referenced "Acquisition."
• The filing repeats that the pro forma information is for informational purposes only and does not represent actual combined historical results or project future results.
• The amendment states it "does not otherwise amend, modify, or update the disclosures contained in the Original 8-K."

Why it may matter This filing reports Item 9.01, which covers financial statements and exhibits and, in this amendment, the inclusion of pro forma financial information related to the Company and Alkeus. This filing does not show why the insider traded or why the company acted.